Preview

User

Not a user? Register with this site Forgot your password?

Head and Neck Tumors (HNT)

Advanced search

“Watch and wait” approach in the treatment of advanced radioiodine refractory differentiated thyroid cancer: a study of barriers and drivers of use

https://doi.org/10.17650/2222-1468-2023-13-4-73-82

Abstract

   Introduction. The multikinase inhibitors have demonstrated high clinical efficacy in treatment of the radioiodine refractory differentiated thyroid cancer. At the same time, the inclusion criteria in the studies has reflected a minimum set of characteristics important for beginning of use of these drugs and an approach that takes into account the tumor progression rate (the volume doubling time) in the absence of clinical manifestations of the disease that have made it possible to individualize the start of therapy.

   Aim. To describe and evaluate the barriers and drivers of use the “watch and wait” approach by Russian oncologists in treatment of the radioiodine refractory thyroid cancer.

   Materials and methods. We conducted 35 structured interviews with oncologists observing patients after radioiodine therapy in order to evaluate the “watch and wait” approach. unfortunately, data on use and prevalence of this approach in Russia are limited. The present study involved the use of deductive content analysis as well as analysis of implementation model of clinical guidelines and included investigation of issue of implementation of the “watch and wait” approach to current practice of therapy for radioiodine refractory differentiated thyroid cancer. One of the main tasks was to determine the influence of external factors on the treatment of this category of patients.

   Conclusion. Barriers and drivers of using “watch and wait” approach in the treatment of differentiated radioiodine refractory thyroid cancer are identified at several levels. for wide use of this approach, it is necessary to involve oncologists taking into account their attitude regarding changes in routine practices, patient expectations and to obtain additional data regarding its long-term effectiveness.

About the Authors

E. V. Borodavina
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Center of Radiology, Ministry of Health of the Russia
Russian Federation

Ekaterina Vladimirovna Borodavina

249036;  4 Koroleva St.; Obninsk


A. Yu. Shurinov
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Center of Radiology, Ministry of Health of the Russia
Russian Federation

249036;  4 Koroleva St.; Obninsk


S. I. Kutukova
Academician I.P. Pavlov First St. Petersburg State Medical University
Russian Federation

197022; 6–8 L’va Tolstogo St.; Saint Petersburg


E. N. Nedozorova
Republican Clinical Oncological Dispensar, Ministry of Health of the Chuvash Republic
Russian Federation

428020; 23 Gladkova St.; Cheboksary


A. V. Malanchuk
Voronezh Regional Clinical Oncological Dispensary
Russian Federation

394036;  4 Vaitsekhovskogo St.; Voronezh


Yu. V. Semenchenko
Voronezh Regional Clinical Oncological Dispensary
Russian Federation

394036; 4 Vaitsekhovskogo St.; Voronezh


S. M. Povarkov
Voronezh Regional Clinical Oncological Dispensary
Russian Federation

394036; 4 Vaitsekhovskogo St.; Voronezh


K. V. Narovenkova
Bryansk Regional Oncological Dispensary
Russian Federation

241050; 96 Stanke Dimitrova Prospekt; Bryansk


A. V. Khodkevich
Bryansk Regional Oncological Dispensary
Russian Federation

241050; 96 Stanke Dimitrova Prospekt; Bryansk


Yu. V. Komoza
Bryansk Regional Oncological Dispensary
Russian Federation

241050; 96 Stanke Dimitrova Prospekt; Bryansk


K. A. Kofanova
Scientific Research Institute of Clinical Oncology Nizhny Novgorod Regional Clinical Oncological Dispensary
Russian Federation

603126; 190 Rodionova St.; Nizhny Novgorod


S. P. Dmitriev
Scientific Research Institute of Clinical Oncology Nizhny Novgorod Regional Clinical Oncological Dispensary
Russian Federation

603126; 190 Rodionova St.; Nizhny Novgorod


E. B. Vasilyeva
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
Russian Federation

454087; 42 Bluchera St.; Chelyabinsk


S. A. Shikhamirova
Republican Cancer Center
Russian Federation

367008; 24 Gaidara Gadzhiyeva St.; Makhachkala


M. N. Gorshenina
Republican Clinical Oncological Dispensary
Russian Federation

424037; 22 Osipenko St.; Yoshkar-Ola


L. N. Volodina
Regional Clinical Oncological Dispensary
Russian Federation

390013; 11 Dzerzhinskogo St.; Ryazan


O. A. Snezhko
Oncological Dispensary
Russian Federation

9344006; 9 Sokolova Prospekt; Rostov-on-Don


O. A. Stativko
City Cancer Hospital No. 1, Moscow Healthcare Department
Russian Federation

117152; Bld. 7, 18a Zagorodnoye Shosse; Moscow


D. V. Xenodokhov
Clinical Oncological Dispensary No. 1, Ministry of Health of the Krasnodar Territory
Russian Federation

350040; 146 Dimitrova St.; Krasnodar


Yu. G. Dzhemageldieva
Clinical Oncological Dispensary No. 1, Ministry of Health of the Krasnodar Territory
Russian Federation

350040; 146 Dimitrova St.; Krasnodar


A. I. Khryapa
Leningrad Regional Clinical Hospital
Russian Federation

194291; Lit. A, Bld. 2, 45 Lunacharskoye Shosse; Saint Petersburg


D. M. Ulimaeva
Leningrad Regional Clinical Hospital
Russian Federation

194291; Lit. A, Bld. 2, 45 Lunacharskoye Shosse; Saint Petersburg


E. M. Dagba
Leningrad Regional Clinical Hospital
Russian Federation

194291; Lit. A, Bld. 2, 45 Lunacharskoye Shosse; Saint Petersburg


M. V. Volkonsky
Moscow Cancer Hospital No. 62, Moscow Healthcare Department
Russian Federation

143515; Moscow Region; Krasnogorskiy Dst.; Stepanovskoye; 1–301427 Istra Village


V. M. Filippova
Moscow Cancer Hospital No. 62, Moscow Healthcare Department
Russian Federation

143515; Moscow Region; Krasnogorskiy Dst.; Stepanovskoye; 1–301427 Istra Village 


M. O. Skorina
Moscow Cancer Hospital No. 62, Moscow Healthcare Department
Russian Federation

143515; Moscow Region; Krasnogorskiy Dst.; Stepanovskoye; 1–301427 Istra Village 


O. V. Romanchuk
Moscow Multidisciplinary Clinical Center “Kommunarka”, Moscow Healthcare Department
Russian Federation

108814; 8 Sosenskiy Stan St.; Moscow


I. I. Andrienko
Klinsk Hospital
Russian Federation

141650; Bld. 3, 9 Lenina St.; Moscow Region; Vysokovsk


M. V. Shorin
Naro-Fominsk Hospital
Russian Federation

143300; 1 Kalinina St.; Moscow Region; Naro-Fominsk 


A. A. Ishchenko
Regional Oncological Dispensary
Russian Federation

664035; 32 Frunze St.; Irkutsk


R. A. Dumbrava
Primorsk Regional Oncological Dispensary
Russian Federation

690105; 59 Russkaya St.; Vladivostok


M. B. Bolieva
Republican Oncological Dispensary, Ministry of Health of the Republic of North Ossetia–Alania
Russian Federation

362002; 2 Zortova St.,; Vladikavkaz


F. V. Tsarakhova
Republican Oncological Dispensary, Ministry of Health of the Republic of North Ossetia–Alania
Russian Federation

362002; 2 Zortova St.,; Vladikavkaz


Z. A. Gojieva
Republican Oncological Dispensary, Ministry of Health of the Republic of North Ossetia–Alania
Russian Federation

362002; 2 Zortova St.,; Vladikavkaz


S. S. Dzhamirzaeva
Republican Oncological Dispensary
Russian Federation

364029; 81 Leonova St.; Grozny


P. Z. Aidaeva
Republican Oncological Dispensary
Russian Federation

364029; 81 Leonova St.; Grozny


M. O. Maximov
Republican Oncological Dispensary, Ministry of Health of the Republic of Khakassia
Russian Federation

655009; 173 Tsukanova St.; Abakan


I. S. Usoltseva
Sakhalin Regional Clinical Oncological Dispensary
Russian Federation

693010; 3 Gorkogo St.; Yuzhno-Sakhalinsk


A. O. Milyukova
Sakhalin Regional Clinical Oncological Dispensary
Russian Federation

693010; 3 Gorkogo St.; Yuzhno-Sakhalinsk


O. V. Toporkova
Tambov Regional Oncological Clinical Dispensary
Russian Federation

392000; 29b Moskovskaya St.; Tambov


V. D. Sychev
Tambov Regional Oncological Clinical Dispensary
Russian Federation

392000; 29b Moskovskaya St.; Tambov


S. A. Rudakov
Tambov Regional Oncological Clinical Dispensary
Russian Federation

392000; 29b Moskovskaya St.; Tambov


S. T. Sagdieva
Regional Clinical Oncological Hospital
Russian Federation

150054; 67 Prospekt Oktyabrya; Yaroslavl


M. A. Klochikhin
Regional Clinical Oncological Hospital
Russian Federation

150054; 67 Prospekt Oktyabrya; Yaroslavl


V. V. Molokova
Zabaikalsky Regional Oncological Dispensary
Russian Federation

672027; 104 Leningradskaya St.; Chita


R. A. Skotnikov
Tula Regional Clinical Oncological Dispensary
Russian Federation

300040; 201a Plekhanova St.; Tula


E. N. Yeremina
Krasnoyarsk Regional Clinical Oncological Dispensary named after A.I. Kryzhanovsky
Russian Federation

660133; 16 1st Smolenskaya St.; Krasnoyarsk


Yu. A. Panaseikin
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Center of Radiology, Ministry of Health of the Russia
Russian Federation

249036;  4 Koroleva St.; Obninsk


Ya. A. Tyugina
Ivanovo Regional Oncological Dispensary
Russian Federation

53040; 5 Lyubimova St.; Ivanovo


Yu. I. Murzina
Oncological Dispensary
Russian Federation

679016; 23 Sholom Aleichema St.; Birobidzhan


S. O. Podvyaznikov
N.N. Blokhin National Medical Russian Research Center of Oncology, Ministry of Health of Russia; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation

115522; 24 Kashirskoye Shosse; 123995; 2/1 Barricadnaya St.; Moscow


References

1. Tuttle R.M., Tala H., Shah J. et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: Using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging sistem. Thyroid 2010;20(12):1341–9. DOI: 10.1089/thy.2010.0178

2. Vaisman F., Momesso D., Bulzico D.A. et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol (Oxf) 2012;77(1):132–8. DOI: 10.1111/j.1365-2265.2012.04342.x

3. Vaisman F., Tala H., Grewal R., Tuttle R.M. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. Thyroid 2011;21(12):1317–22. DOI: 10.1089/thy.2011.0232

4. Haugen B.R., Sherman S.I. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev 2013;34(3):439–55. DOI: 10.1210/er.2012-1038

5. Bockisch A., Brose M., Nutting C. et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer (DTC): the phase III DECISION trial. Exp Clin Endocrinol Diabetes 2014;384(9940):319–28. DOI: 10.1055/s-0034-1372011

6. Schlumberger M., Tahara M., Wirth L.J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372(7):621–30. DOI: 10.1056/nejmoa1406470

7. Tuttle R.M., Brose M.S., Grande E. et al. Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab 2017;31(3):295–305. DOI: 10.1016/j.beem.2017.04.014

8. Tryakin A.A., Besova N.S., Volkov N.M. et al. General principles of antitumor drug therapy. Zlokachestvennye opuholi = Malignant Tumors 2023;13(3s2–1):28–41. (In Russ.). DOI: 10.18027/2224-5057-2023-13-3s2-1-28-41

9. Kim H., Park S.Y., Jung J. et al. Improved survival after early detection of asymptomatic distant metastasis in patients with thyroid cancer. Sci Rep 2019;9:18745. DOI: 10.1038/s41598-019-55370-w

10. Dadu R., Cabanillas M.E. Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: Current state of the art and future directions. Minerva Endocrinol 2012;37(4):335–56.

11. Schutz F.A.B., Je Y., Richards C.J., Choueiri T.K. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 2012;30(8):871–7. DOI: 10.1200/JCO.2011.37.1195

12. Zettinig G., Fueger B.J., Passler C. et al. Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma – surgery or conventional therapy? Clin Endocrinol (Oxf) 2002;56(3):377–82. DOI: 10.1046/j.1365-2265.2002.01482.x

13. Chiu A.C., Delpassand E.S., Sherman S.I. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 1997;82(11):3637–42. DOI: 10.1210/jcem.82.11.4386

14. Henriques De Figueiredo B., Godbert Y., Soubeyran I. et al. Brain metastases from thyroid carcinoma: a retrospective study of 21 patients. Thyroid 2014;24(2):270–6. DOI: 10.1089/thy.2013.0061

15. Tuttle R.M. Initial treatment of progressive differentiated thyroid cancer. Clin Adv Hematol Oncol 2016;14(5 Suppl. 9):3–6.

16. Fischer F., Lange K., Klose K. et al. Barriers and strategies in guideline implementation – a scoping review. Healthc 2016;4(43):36. DOI: 10.3390/healthcare4030036


Review

For citations:

Borodavina E.V., Shurinov A.Yu., Kutukova S.I., Nedozorova E.N., Malanchuk A.V., Semenchenko Yu.V., Povarkov S.M., Narovenkova K.V., Khodkevich A.V., Komoza Yu.V., Kofanova K.A., Dmitriev S.P., Vasilyeva E.B., Shikhamirova S.A., Gorshenina M.N., Volodina L.N., Snezhko O.A., Stativko O.A., Xenodokhov D.V., Dzhemageldieva Yu.G., Khryapa A.I., Ulimaeva D.M., Dagba E.M., Volkonsky M.V., Filippova V.M., Skorina M.O., Romanchuk O.V., Andrienko I.I., Shorin M.V., Ishchenko A.A., Dumbrava R.A., Bolieva M.B., Tsarakhova F.V., Gojieva Z.A., Dzhamirzaeva S.S., Aidaeva P.Z., Maximov M.O., Usoltseva I.S., Milyukova A.O., Toporkova O.V., Sychev V.D., Rudakov S.A., Sagdieva S.T., Klochikhin M.A., Molokova V.V., Skotnikov R.A., Yeremina E.N., Panaseikin Yu.A., Tyugina Ya.A., Murzina Yu.I., Podvyaznikov S.O. “Watch and wait” approach in the treatment of advanced radioiodine refractory differentiated thyroid cancer: a study of barriers and drivers of use. Head and Neck Tumors (HNT). 2023;13(4):73-82. (In Russ.) https://doi.org/10.17650/2222-1468-2023-13-4-73-82

Views: 455


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2222-1468 (Print)
ISSN 2411-4634 (Online)
"ABV-press" publishing house
Kashirskoye sh., 23/2, RCRC. N.N.Blokhin, 23rd floor, cab. 2313, 
115478, Moscow
E-mail: info@hnonco.ru Processing of personal data
supported by NEICON (Elpub lab)